Ildong great likelihood to sell strongly 'Otrivin' by GSK

Final stage for negotiation, GSK & Ildong said, “Nothing is fixed”

Lamisil is expected to be sold by Zuellig Pharma Korea

Ildong pharmaceuticals has the most potential of otc vendor for 10 GSK　items.

 

It is possible that A distributor, Zuellig Pharma Korea will be charge of selling Lamisil.

 

According to the industry on the 26th, GSK, Ildong Pharmaceuticals and Zuellig Pharma Korea are in the last negotiations over the right to sell 10 generic drugs.

 

A retailer said, "Since last September, Ildong Pharmaceuticals is going to distribute GSK products.

 

The industry has already begun.

 

The preparations are almost finished".

 

"Zuellig Pharma Korea has recently been added as a distributor and is in charge of selling Lamisil" he said.

 

GSK and Ildong Pharmaceuticals said, "There is no confirmation yet".

 

However, retailers and pharmacies believe that Ildong Pharmaceuticals was determined to be the main seller of 10 items.

 

The 10 items to be negotiated are Lamisil, Otrivin, Voltaren, Nicotine-L, Theraflu, Sensodyne, Breathe right, Zantac, Polident, and Driclor.

 

Among them, Lamisil is expected to be sold by Zuellig Pharma Korea and Ildong Pharmaceuticals to sell the remaining nine items.

 

However, as negotiations are still underway, each company's products may change.

 

In addition to Lamisil, it is likely that Zuellig Pharma Korea will be responsible for selling more products.

 

An official at GSK said, "We can't formalize anything until the agreement is signed.

 

Nothing has been decided yet." .

 

An official of Ildong Pharmaceuticals said, "We cannot confirm when the contract is finalized.

 

We will announce it after all contracts are concluded".

 

Dong-wha Pharmaceuticals has distributed 10 GSK generic drugs.

 

Originally, the copyright contract was until 2020, but the merger of GSK and Pfizer Healthcare prevented the company from maintaining its existing contract.

 

Dong-wha Pharmaceuticals recently announced that it will end its generic drug supply contract with GSK on Dec 31.

 

Dong-wha Pharmaceuticals is in the process of returning GSK products at pharmacies, and GSK is said to have almost stopped sending out 10 products to which the copyright is transferred.

 

Next year, a new dealer will settle inventory with Dong-wha Pharmaceuticals before supplying the product.